AEON Valuation Metrics
FCF$-17.31M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
AEON Biopharma Inc - Class A
Exchange: NYSE MKTSector: HealthcareIndustry: Biotechnology
Priveterra Acquisition Corp - Class A
Did you know?
Price sits at 49% of its 52-week range.
Current Price
$0.89
-9.16%Profile
Valuation (TTM)
Market Cap$10.52M
P/E-0.27
EV—
P/B—
Shares Out11.84M
P/Sales—
Revenue$0.00
EV/EBITDA—
AEON Biopharma Inc - Class A (AEON) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →AEON Valuation & Fair Value Analysis
AEON Biopharma Inc - Class A (AEON) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -0.27. PEG ratio is 0.00.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of AEON Biopharma Inc - Class A's intrinsic value.